NICI Wellness
Loading Chart...
NICI Wellness Stocks
| Symbol | Company Name | Last Price | Open |
Previous Close |
Volume |
|---|---|---|---|---|---|
| AMRS | Amyris Inc | $13.82 | 15.15 | 15.26 | 2.52M |
| ARNA | Arena Pharmaceuticals | $79.49 | 79.42 | 80.10 | 323.91K |
| CARA | Cara Therapeutics | $19.26 | 19.33 | 19.82 | 389.87K |
| CWBHF | Charlotte's Web Holdings Inc | $4.90 | 5.00 | 5.20 | 430.58K |
| EOFBF | Ecofibre Ltd | $1.32 | 1.36 | 1.30 | 75.00 |
| GWPH | Gw Pharma ADR | $214.85 | 215.00 | 215.00 | 1.05M |
| NBEV | New Age Beverages Corp | $2.70 | 2.84 | 2.84 | 2.57M |
Articles About NICI Wellness Stocks
-
The Courage of Your Convictions Is Your Key to the Biggest Gains in Cannabis
-
Congratulations on Your 90% Gains From GW Pharmaceuticals
-
Weekly Progress Report: GWPH’s $7.2 Billion Price Tag
-
Acquisition Alert: GWPH Enters the Merger Market
-
As Big Pharma Makes Its Move Into Cannabis, You Get to Profit
-
New Year, New NICILytics Updates: Here Are the First Companies to Usher in Earnings Season
-
GW Pharmaceuticals PLC Sponsored ADR
-
Weekly Progress Report: Your Post-Election Day Recap Is Full of New Opportunities
-
Why One Model Portfolio Stock Is Crushing Expectations This Week
-
Weekly Progress Report: This Is the Boost You Can Expect for Cannabis Profits in 2021 (And Beyond)
-
Earnings Season Is in Full Swing: Here Are the Companies Offering the Best Profit Opportunities
-
Competition Is Heating up in the Cannabis Pharmaceuticals Market
-
Weekly Progress Report: What You Need to Know About Jushi’s Big Win on the West Coast
-
Netflix Took 10 Years to Accomplish What This Cannabis Company Could Do in Just 3
-
Let’s Take This Profit and Deploy It on Our Next Big Opportunity
-
Weekly Progress Report: Meet the Next Big Name in Cannabis Pharmaceuticals
-
Weekly Progress Report: Cannabis Is Going Global Thanks to These 3 Portfolio Companies
-
Snowflake Launches IPO Fever
-
25 Answers to 25 Questions That Will Help You Get the Most Out of Cannabis Investing
-
3 New Reports: 60 Dispensaries, a Phase III Trial Update, and a 245% in Gross Profits Take the Spotlight